Drugs / cP12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06814717 | May 2025 → Jul 2026 overdue | — | Neomatrix Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cP12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06814717 ↗ |
| Modality | Peptide | “cP12 is a novel fibronectin derived, 14-mer peptide” NCT06814717 ↗ |
| Route | Intravenous | “administered over approximately 30 minutes by intravenous (IV) infusion” NCT06814717 ↗ |